Edition:
United States

Protagonist Therapeutics Inc (PTGX.OQ)

PTGX.OQ on NASDAQ Stock Exchange Global Market

7.45USD
13 Jul 2018
Change (% chg)

$0.02 (+0.27%)
Prev Close
$7.43
Open
$7.43
Day's High
$7.55
Day's Low
$7.29
Volume
19,133
Avg. Vol
78,215
52-wk High
$23.68
52-wk Low
$5.92

Chart for

About

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing... (more)

Overall

Beta: --
Market Cap(Mil.): $157.97
Shares Outstanding(Mil.): 21.20
Dividend: --
Yield (%): --

Financials

  PTGX.OQ Industry Sector
P/E (TTM): -- 214.97 33.20
EPS (TTM): -1.69 -- --
ROI: -32.09 -3.79 13.23
ROE: -32.21 -5.32 15.28

BRIEF-Protagonist Therapeutics Reports Q1 Net Loss Per Share $0.36

* PROTAGONIST THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 09 2018

BRIEF-Protagonist Therapeutics Discontinues Phase 2B Propel Trial Of PTG-100

* PROTAGONIST THERAPEUTICS DISCONTINUES PHASE 2B PROPEL TRIAL OF PTG-100 FOR THE TREATMENT OF ULCERATIVE COLITIS FOLLOWING INTERIM ANALYSIS

Mar 26 2018

BRIEF-Protagonist Therapeutics Q4 Loss Per Share $0.15

* PROTAGONIST THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

Mar 07 2018

BRIEF-FDA Grants Orphan Drug Designation For Protagonist Therapeutics' PTG-300

* FDA GRANTS ORPHAN DRUG DESIGNATION FOR PROTAGONIST THERAPEUTICS' PTG-300 FOR THE TREATMENT OF BETA-THALASSEMIA Source text for Eikon: Further company coverage:

Mar 06 2018

Earnings vs. Estimates